Previous 10 | Next 10 |
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced tod...
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation (DCF and EV/Sales) to derive our $34 PT. Our assumptions include: Rhopressa: U.S. peak-sales of $1...
The following slide deck was published by Aerie Pharmaceuticals, Inc. in conjunction with this Read more ...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provid...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announc...
Investors know that drug development is an expensive and risky endeavor. Most drug candidates fail clinical trials, which is why the direct research and development necessary for each drug candidate that finally makes it to market costs hundreds of millions of dollars. That makes successful drug...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announc...
Image source: The Motley Fool. Aerie Pharmaceuticals Inc (NASDAQ: AERI) Q4 2019 Earnings Call Feb 20, 2020 , 5:00 p.m. ET Operator Continue reading
Shares of Aerie Pharmaceuticals (NASDAQ: AERI) jumped more than 14% after the company reported fourth-quarter and full-year 2019 operating results. The commercial-stage pharmaceutical company handily beat expectations for product revenue in the final three months of last year. The business ...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...